The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Home Explore BioSpectrum Asia Feb 2023
View in Fullscreen

CANCER THERAPEUTICS GAINING GROUND IN APAC
Cancer, the leading cause of death in most parts of the world, is a veritable Achilles heel for the pharma industry. Not surprising that pharma companies continue to dedicate a significant part of their R&D budget for Oncology. Cancer medicine spending rose to $185 billion globally in 2021 and is expected to reach more than $300 billion by 2026, as per IQVIA. China’s oncology spending now exceeds the rest of emerging countries and is driven by expanded access to new therapies
and offset by lower prices. Chinese and other Asian cancer drug developers are at the forefront of driving innovation in this space. The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. The next wave of innovations making headlines in the cancer space include immunotherapies, vaccines, CAR-T therapies, PD-1/L1 inhibitors, light-activated drugs etc. Many drug makers in Asia are investing in new science and hope to develop the next holy grail in oncology. Let’s take a deep dive into the status of cancer drug research and development in the Asia Pacific (APAC).

Like this book? You can publish your book online for free in a few minutes!
Share

Related Publications

Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by MMA Media, 2023-02-05 23:10:35

BioSpectrum Asia Feb 2023

CANCER THERAPEUTICS GAINING GROUND IN APAC
Cancer, the leading cause of death in most parts of the world, is a veritable Achilles heel for the pharma industry. Not surprising that pharma companies continue to dedicate a significant part of their R&D budget for Oncology. Cancer medicine spending rose to $185 billion globally in 2021 and is expected to reach more than $300 billion by 2026, as per IQVIA. China’s oncology spending now exceeds the rest of emerging countries and is driven by expanded access to new therapies
and offset by lower prices. Chinese and other Asian cancer drug developers are at the forefront of driving innovation in this space. The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. The next wave of innovations making headlines in the cancer space include immunotherapies, vaccines, CAR-T therapies, PD-1/L1 inhibitors, light-activated drugs etc. Many drug makers in Asia are investing in new science and hope to develop the next holy grail in oncology. Let’s take a deep dive into the status of cancer drug research and development in the Asia Pacific (APAC).

Keywords: Cancer care,Biopharma

"We Communicate directly with Life-Science Leaders and BioPharma Executives World-Wide" For More information , Please contact [email protected] www.biospectrumasia.com www.biospectrumindia.com


High Quality Grade Plasmid and Minicircle DNA The better way to DNA! PlasmidFactory.com PlasmidFactory GmbH & Co. KG Meisenstraße 96 | D-33607 Bielefeld | Germany | Fon +49 521 2997 350 grafeting gmbh | visuals: stock.adobe.com Starting material for GMP production of mRNA, viral vectors & CAR-T cells Now in LARGE scale!


Click to View FlipBook Version